DDInter1852 DDInter856
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Treprostinil {u} (Compound) resembles {v} (Compound) Latanoprost
Treprostinil {u} (Compound) binds {v} (Gene) P2RY12
Treprostinil {u} (Compound) upregulates {v} (Gene) IL4R
Treprostinil {u} (Compound) is included by {v} (Pharmacologic Class) Vasodilation
Treprostinil {u} (Compound) downregulates {v} (Gene) CNDP2
Treprostinil {u} (Compound) causes {v} (Side Effect) Palpitations
Treprostinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reteplase
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Treprostinil (Compound) resembles Latanoprost (Compound)
Treprostinil (Compound) binds P2RY12 (Gene)
Treprostinil (Compound) upregulates IL4R (Gene)
Treprostinil (Compound) is included by Vasodilation (Pharmacologic Class)
Treprostinil (Compound) downregulates CNDP2 (Gene)
Treprostinil (Compound) causes Palpitations (Side Effect)
Treprostinil may cause a minor interaction that can limit clinical effects when taken with Capsicum
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Reteplase
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Treprostinil may lead to a major life threatening interaction when taken with Ramucirumab